With the appointment of pharmaceuticals veteran Peter Stein as Director of the US FDA’s Office of New Drugs in December of 2018 comes the promise of further restructuring at the agency. The appointment announcement came alongside the news that seasoned FDA veteran Robert Temple would be moving from his post as acting Deputy Director of ODE I to serve as a consultant on matters of clinical trials to both Stein and other FDA officials. Read more about the changes to FDA staffing in this informative Pink Sheet article.